Trinity Legacy Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.13M Buy
3,397
+137
+4% +$139K 0.68% 54
2025
Q4
$3.5M Buy
3,260
+47
+1% +$44.9K 0.8% 51
2025
Q3
$2.77M Buy
3,213
+308
+11% +$229K 0.64% 58
2025
Q2
$2.29M Buy
2,905
+2,625
+938% +$2.04M 0.56% 61
2025
Q1
$209K Buy
+280
New +$233K 0.05% 90

Other funds holding LLY

Trinity Legacy Partners's LLY Position: Q1 2026 in Review

Trinity Legacy Partners increased its Eli Lilly (LLY) stake by 4.2% in Q1 2026, buying an estimated $139K and bringing the position to 3,397 shares worth $3.13M. The position accounts for 0.68% of the portfolio, ranked #54.

Trinity Legacy Partners first reported a position in LLY in Q1 2025 and has held it in 5 quarters since. The position peaked at $3.5M in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Trinity Legacy Partners held 3,397 shares of Eli Lilly worth $3.13M as of Q1 2026.
  • Trinity Legacy Partners bought 137 Eli Lilly shares in Q1 2026, an estimated $139K.
  • Eli Lilly made up 0.68% of Trinity Legacy Partners's portfolio in Q1 2026, its #54 holding.
  • Trinity Legacy Partners first reported a position in Eli Lilly in Q1 2025 and has held it in 5 quarters since.
  • Trinity Legacy Partners's Eli Lilly position peaked at $3.5M in Q4 2025.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Trinity Legacy Partners's 13F filing for Q1 2026, filed 16 Apr 2026.